NCT02296918 2025-12-19Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLAcerta Pharma BVPhase 1 Completed69 enrolled
NCT02303392 2025-06-10Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin LymphomaOhio State University Comprehensive Cancer CenterPhase 1 Completed34 enrolled 14 charts